The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally
Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment opportunities
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Market Conditions Report applies the latest data to analyze current activities in the life sciences deal landscape.
Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand
Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting firm, on Sept. 15, 2008, the same day that Lehman Brothers filed for bankruptcy and Merrill Lynch sold itself to Bank of America.
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2020 Year End Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape.
Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk facing public biopharma companies — single asset failures — and what they can do during this time of robust capital.
CATEGORIES News Events Publications ARCHIVE Panel Recording: The Unexpected IPO Boom in Biopharma in Q2 Locust Walk partnered with Applied
CATEGORIES News Events Publications ARCHIVE Geoff Meyerson to Moderate Panel at Crush Life Sciences Board Meeting The Crush Life Sciences
CATEGORIES News Events Publications ARCHIVE Hayato Watanabe, Locust Walk’s SVP, Head of Asia, to Speak on a Panel at BIO